The clipboard was an excellent place to begin. In December 2015, a Columbus startup called CrossChx announced Queue, a hospital check-in kiosk that promised to replace the familiar ritual of handwriting information someone else would type into a computer. The price started at $299 a month. The ambition was legible: get the right patient into the right record, with less waiting around.
- Olive automated hospital administration, from insurance checks to prior authorization.
- A $400 million funding round valued it at $4 billion in July 2021.
- It announced its wind-down in October 2023; several products went to new owners.
Eight years after that kiosk announcement, the company, by then called Olive, was winding down. It had pursued something much larger than a better waiting room. It wanted to connect healthcare’s disconnected machinery. The interesting question is how a business travels from replacing a clipboard to promising an entire industry a different operating system.
01 / The patient was the process
Sean Lane and Brad Mascho founded CrossChx in 2012. Its early identity-resolution software addressed a deceptively ordinary problem: medical records could fail to match the person standing at reception. SafeChx was offered free to hospitals; Queue put registration into a paid physical product. This was healthcare technology aimed at the administrative plumbing.
Lane’s background helps explain the attraction. He had served as an Air Force intelligence officer and worked at the NSA. As he later discussed with MATTER, his path into healthcare entrepreneurship was influenced by prescription drug abuse in his hometown. Finding connections in messy information was familiar territory. Hospitals supplied an abundance of messy information.
The team first deployed Olive in 2017. The work shifted toward high-volume administrative routines. Check insurance. Handle authorization steps. Move information through systems that did not conveniently cooperate. For a hospital, the attraction was practical: fewer staff hours consumed by repetitive work, with more capacity available for the tasks that required people.
02 / Give the software a job
Olive described its offering as an AI workforce. That language made complicated software sound like something a hospital already understood how to acquire: another pair of hands. General Catalyst’s investment case described healthcare-specific AI-as-a-Service that worked with existing electronic health records and other software, with learning intended to improve performance across providers.
Its market sat between general automation platforms, healthcare workflow specialists and established revenue-cycle vendors. The pitch combined industry knowledge with execution inside existing workflows. A generic automation toolkit gives a buyer building blocks; Olive proposed to bring healthcare expertise along with the automation. Hospitals and insurers were the business customers. Their staff were the daily users.
- 01 Verify
coverage - 02 Obtain
authorization - 03 Submit
the claim
The business model was enterprise automation sold to institutions. Olive also experimented with a wider platform. Olive Helps was announced as a free desktop download in 2021. Developers could build tools called Loops using a JavaScript and TypeScript development kit. The repository describes compiling and installing those Loops: a concrete artifact beneath the expansive platform language.
The company also bought capabilities. Verata Health brought prior authorization technology in 2020. Empiric Health added clinical analytics in 2021. Healthcare IP took Olive into clearinghouse services. The portfolio was broadening from administrative tasks into payments, clinical intelligence and infrastructure.
03 / The promise gets expensive
Capital arrived quickly. A December 2020 financing brought in $225.5 million. The following July, a $400 million round led by Vista Equity Partners, with Base10 participation, priced Olive at $4 billion. Olive then reported cumulative financing of $902 million. That figure describes money raised, not revenue earned or savings delivered.
Its reach appeared substantial. Olive reported being deployed in more than 900 hospitals across over 40 states in July 2021. AWS became a cloud and developer partner. GuideWell and its subsidiary Florida Blue announced a collaboration on automated authorization approvals in February 2022. These were recognizable institutions attached to a recognizable problem.
Inside the company, expansion had its own vocabulary. The Grid, introduced in 2020, let employees work from locations around the country. It widened the hiring map. But a wider hiring map and a wider product catalog also created more work to coordinate.
By April 2022, Axios was reporting concerns about Olive’s offerings and how customer savings were measured. In July, Olive cut 450 employees. Lane acknowledged that rapid growth and insufficient focus had overloaded product and engineering. Economic conditions were part of the explanation; execution was another part.
“Our fast-paced growth and lack of focus strained our product and engineering resources”
Sean Lane · July 2022
The response was to narrow the business around revenue-cycle management for providers and utilization management for payers. Lane said those areas accounted for about 80% of revenue and pipeline. The change had a clear logic: concentrate on where customers and commercial demand already were. It arrived after the organization had grown around a larger set of ambitions.
04 / The company ends. The work continues.
In April 2023, Availity announced an agreement to acquire Olive’s utilization-management business, including customer contracts and key staff. In October, Olive announced the sale of clearinghouse and patient access units to Waystar and its prior authorization business to Humata Health. The remaining company would wind down.
Waystar later disclosed $10 million in consideration for certain Olive assets. Put that beside the $4 billion valuation carefully. One number priced a financing round; the other bought specific assets. Neither supplies a complete accounting of investor recoveries. They do show how differently a broad promise and a bounded operating business can be priced.
For a buyer or founder, the practical lesson is to make the unit of proof smaller. Pick a workflow. Count its exceptions, maintenance and rework. Measure the human effort left after installation. That is an editorial inference from Olive’s history, rather than a verdict on every deployment.
Automation is a difficult bargain when rules keep changing, inputs vary or people must rescue too many failed steps. A busy software dashboard can coexist with a busy employee. Olive’s remaining products found buyers because the underlying tasks still needed doing. The clipboard had been a good place to start. The hard part was proving, repeatedly, that it could finally be put away.